Baseline characteristics of patients in the Sailing Study
| Variables | Conbercept (95% CI) | Laser (95% CI) | P value | ||
| (n=125) | (n=123) | ||||
| Age (years) | 58.9±8.5 | (57.43 to 60.42) | 58.7±8.8 | (57.18 to 60.30) | 0.863 |
| Sex, n (%) | 0.527 | ||||
| Male | 66 (52.8) | (51.31 to 53.27) | 60 (48.8) | (47.27 to 49.23) | |
| Female | 59 (47.2) | (46.73 to 48.69) | 63 (51.2) | (50.77 to 52.73) | |
| BMI (kg/m2) | 24.2±3.4 | (24.13 to 24.50) | 25.0±4.5 | (24.83 to 25.32) | 0.095 |
| Duration of diabetes (years) | 12.3±7.0 | (12.16 to 12.92) | 11.0±6.3 | (10.77 to 11.44) | 0.138 |
| HbA1c | 7.06±1.19 | (6.85 to 7.27) | 7.13±1.192 | (6.92 to 7.35) | 0.646 |
| Study eye, n (%) | 0.881 | ||||
| Right | 72 (57.6) | (56.21 to 58.16) | 72 (58.5) | (57.19 to 59.13) | |
| Left | 53 (42.4) | (41.84 to 43.79) | 51 (41.5) | (40.87 to 42.81) | |
| BCVA (ETDRS letter) | 56.6±11.5 | (54.50 to 59.19) | 57.6±11.5 | (54.59 to 59.62) | 0.505 |
| IOP (mm Hg) | 15.2±3.0 | (14.62 to 15.68 | 15.1±3.4 | (14.45 to 15.66) | 0.819 |
| CRT (μm) | 480.0±180.0 | (476.36 to 495.90) | 470.0±160.0 | (464.09 to 481.28) | 0.753 |
| TMV (mm3) | 9.9±1.2 | (9.45 to 10.39) | 10.1±1.4 | (9.68 to 10.72) | 0.534 |
| Leakage area (mm2) | 28.2±11.0 | (26.20 to 30.11) | 27.8±10.8 | (25.92 to 29.76) | 0.820 |
| NEI VFQ-25 total score | 65.9±17.1 | (62.88 to 68.93) | 66.7±17.9 | (63.47 to 69.85) | 0.733 |
| History of laser treatments, n (%) | 0.622 | ||||
| Yes | 77 (61.60) | (60.14 to 62.06) | 72 (58.54) | (57.25 to 59.19) | |
| No | 48 (38.40) | (37.94 to 39.86) | 51 (41.46) | (40.81 to 42.75) | |
| History of ocular anti-VEGF treatments, n (%) | 0.098 | ||||
| Yes | 14 (11.20) | (10.08 to 11.30) | 23 (18.70) | (17.61 to 19.13) | |
| No | 111 (88.80) | (88.70 to 89.92) | 100 (81.30) | (80.87 to 82.39) | |
BCVA, best-corrected visual acuity; BMI, Body Mass Index; CRT, central retinal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; HbA1c, haemoglobin A1c; IOP, intraocular pressure; NEI VFQ-25, 25-Item National Eye Institute Visual Function Questionnaire; TMV, total macular volume; VEGF, vascular endothelial growth factor.